Jump to content

James C. Tsai

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Melcous (talk | contribs) at 10:55, 17 June 2020 (MOS:CREDENTIALS). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

James C. Tsai
Born1963
EducationAmherst College, Stanford University School of Medicine, Owen Graduate School of Management at Vanderbilt University
Medical career
ProfessionOphthalmologist
InstitutionsVanderbilt University School of Medicine, Harkness Eye Institute at Columbia University College of Physicians and Surgeons, Yale University School of Medicine, New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai
Sub-specialtiesGlaucoma and Glaucoma surgery
WebsiteJames C. Tsai at Mount Sinai

James C. Tsai is President, New York Eye and Ear Infirmary of Mount Sinai,[1][2] the USA's first and longest-operating specialty hospital, founded in 1820.[3] He also serves as the Delafield-Rodgers Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and serves as System Chair of the Department of Ophthalmology at the Mount Sinai Health System.

Tsai published the first taxonomy of medication compliance and adherence barriers in patients with glaucoma, the initial paper describing the isolated-check visual evoked potential (icVEP) technology for patients with glaucoma,[4] and one of the first studies evaluating the use of erythropoietin for neuroprotection in an animal model of glaucoma.

Biography

Tsai received his B.A. in Neuroscience from Amherst College in 1985, his M.D. from Stanford University School of Medicine in 1989, and his M.B.A. in Business Administration in 1998 from the Owen Graduate School of Management at Vanderbilt University. He served his residency in Ophthalmology at Doheny Eye Institute at the University of Southern California, 1990-1993, his fellowship in glaucoma at Bascom Palmer Eye Institute, University of Miami, 1993-1994, and another fellowship in glaucoma at Moorfields Eye Hospital and the Institute of Ophthalmology, London, 1994-1995.

Former positions include Assistant Professor of Ophthalmology and Visual Sciences and Residency Program Director, Department of Ophthalmology and Visual Sciences at Vanderbilt University School of Medicine,[5] as well as Associate Professor of Ophthalmology and Director, Glaucoma Division, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons.[1]

Tsai then served as Robert R. Young Professor of Ophthalmology and Visual Science and Chair, Department of Ophthalmology and Visual Science, Yale University School of Medicine[6] and Chief of Ophthalmology, Yale-New Haven Hospital.[7]

Research

Tsai's research includes the identification of neuroprotective molecules that can shield the optic nerve from damage without lowering intraocular pressure, evaluation of medical adherence and surgical outcomes in patients with glaucoma, and development of advanced vision testing techniques.[8]

His more recent research includes the long-term safety and efficacy of the Ahmed Shunt versus the Baerveldt Shunt Implant, optimizing and enhancing medication adherence in patients with glaucoma, and understanding the role of inflammation in the pathogenesis and treatment of glaucoma.[9][10][11][12]

Professional affiliations and activities

Tsai has served as editorial board member for nine scientific journals. He has held the follow leadership positions:

Honors

Publications

Author of more than 170 scientific articles, chapters, and textbooks, including the Oxford American Handbook of Ophthalmology and Medical Management of Glaucoma (4 editions).[24][25] Tsai has served as editorial board member for 9 medical journals and manuscript reviewer for over 90 additional scientific journals.

His most cited journal articles are:

  • Sivak-Callcott, JA; O'Day, DM; Gass, JD; Tsai, JC (Oct 2001). "Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma". Ophthalmology. 108 (10): 1767–76. doi:10.1016/s0161-6420(01)00775-8. (cited 373 times according to GoogleScholar [26])
  • Tsai, JC; McClure, CA; Ramos, SE; Schlundt, DG; Pichert, JW (2003). "Compliance Barriers in Glaucoma: A Systematic Classification". J Glaucoma. 12 (5): 393–8. doi:10.1097/00061198-200310000-00001. PMID 14520147. (cited 333 times according to GoogleScholar [26])
  • Bloom, PA; Tsai, JC; Sharma, K; Miller, MH; Rice, NS; Hitchings, RA; Khaw, PT (Sep 1997). ""Cyclodiode": Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma". Ophthalmology. 104 (9): 1508–20. (cited 310 times according to GoogleScholar[26])
  • Salchow, DJ; Oleynikov, YS; Chiang, MF; Kennedy-Salchow, SE; Langton, K; Tsai, JC; Al-Aswad, LA (May 2006). "Retinal nerve fiber layer thickness in normal children measured with optical coherence tomography". Ophthalmology. 113 (5): 786–91. doi:10.1016/j.ophtha.2006.01.036. (cited 175 times according to GoogleScholar[26])
  • Tsai, JC; Johnson, CC; Dietrich, MS (Sep 2003). "The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma: a single-surgeon comparison of outcome". Ophthalmology. 110 (9): 1814–21. doi:10.1016/s0161-6420(03)00574-8. (cited 194 times according to GoogleScholar[26])

References

  1. ^ a b "James C. Tsai Named President of New York Eye and Ear Infirmary of Mount Sinai". Retrieved September 25, 2017.
  2. ^ "Mount Sinai Launches Eye Research Institute". Retrieved 25 September 2017.
  3. ^ "Meet Our Doctors – The Advanced Center for Eyecare".
  4. ^ Kent, Christopher (15 October 2006). "icVEP: A New Way to Catch Early Glaucoma?". Review of Ophthalmology. Retrieved 25 September 2017.
  5. ^ "Faculty Profiles, Vanderbilt University". Retrieved 25 September 2017.
  6. ^ "Glaucoma Foundation: James C. Tsai, MD". Retrieved 25 September 2017.
  7. ^ "Yale Eye" (PDF). Retrieved 25 September 2017.
  8. ^ "National Eye Institute". Retrieved 25 September 2017.
  9. ^ "Study compares drainage devices". Ophthalmology Times. 1 April 2012. Retrieved 14 September 2019.{{cite web}}: CS1 maint: url-status (link)
  10. ^ Tsai, James (June 2006). "The Ahmed Shunt versus the Baerveldt Shunt for Refractory Glaucoma II". American Academy of Ophthalmology.{{cite web}}: CS1 maint: url-status (link)
  11. ^ Dietrich, Mary S.; Kammer, Jeffrey A.; Johnson, Cameron Campbell; Tsai, James C. (2006). "The Ahmed shunt versus the Baerveldt shunt for refractory glaucoma II: longer-term outcomes from a single surgeon". undefined. Retrieved 2019-09-14.
  12. ^ Sides Media, www sidesmedia com. "Glaucoma Today - When Tube Shunts Fail". Glaucoma Today. Retrieved 2019-09-14.
  13. ^ "About IJCAHPO". www.jcahpo.org. Retrieved 2019-08-29.
  14. ^ "Section for Health Care Systems 2019 Regional Policy Board Representatives" (PDF). American Hospital Association. Retrieved 14 September 2019.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "James C. Tsai, M.D., M.B.A." National Eye Institute (NEI), National Institutes of Health.{{cite web}}: CS1 maint: url-status (link)
  16. ^ "National Institutes of Health - NEI - Spokesperson Bio". Retrieved 11 October 2017.
  17. ^ "The American Ophthalmalogical Society". Retrieved 25 September 2017.
  18. ^ "Chinese American Ophthalmological Society". Retrieved 25 September 2017.
  19. ^ "Glaucoma specialist is named chair of ophthalmology". Yale School of Medicine.{{cite web}}: CS1 maint: url-status (link)
  20. ^ "COS Annual Meeting and Exhibition". Canadian Ophthalmological Society. Retrieved 10 September 2019.
  21. ^ "Doximity.com". Retrieved 25 September 2017.
  22. ^ "Amherst College Corporation and Board of Trustees". Retrieved 25 September 2017.
  23. ^ "New York Academy of Medicine". Retrieved 25 September 2017.
  24. ^ "Oxford University Press". Retrieved 25 September 2017.
  25. ^ "Medical Management of Glaucoma". Retrieved 25 September 2017.
  26. ^ a b c d e [1] Google Scholar author page. Accessed April 25, 2019